{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T22:22:05Z","timestamp":1775859725816,"version":"3.50.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T00:00:00Z","timestamp":1681084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2021-I2M-1-007"],"award-info":[{"award-number":["2021-I2M-1-007"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81825002"],"award-info":[{"award-number":["81825002"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Outstanding Young Scientist Program"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The strategy of blood pressure intervention in the elderly hypertensive patients (STEP) trial reported the cardiovascular benefit of intensive systolic blood pressure (SBP) control in patients with hypertension. The association between intensive SBP lowering and the risk of new-onset diabetes is unclear. This study aimed to evaluate the effect of intensive SBP lowering on the incidence of new-onset diabetes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Participants in STEP who had baseline fasting serum glucose (FSG) concentrations &amp;lt;7.0 mmol\/L and no history of diabetes or hypoglycaemic medication use were included. The primary outcome was new-onset diabetes defined as the time to first occurrence of FSG concentrations \u22657.0 mmol\/L. The secondary outcome was new-onset impaired fasting glucose (FSG: 5.6\u20136.9 mmol\/L) in participants with normoglycemia. A competing risk proportional hazards regression model was used for analysis. The cohort comprised 5601 participants (mean age: 66.1 years) with a mean baseline SBP of 145.9 mmHg. Over a median follow-up of 3.42 years, 273 (9.6%) patients in the intensive SBP group (target, 110 to &amp;lt;130 mmHg) and 262 (9.5%) in the standard SBP group (target, 130 to &amp;lt;150 mmHg) developed diabetes (adjusted hazard ratio, 1.01; 95% confidence interval (CI), 0.86\u20131.20). The adjusted hazard ratio for the secondary outcome was 1.04 (95% CI, 0.91\u20131.18). The mean highest FSG concentration during the follow-up was 5.82 and 5.84 mmol\/L in the intensive and standard groups, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Intensive SBP lowering is not associated with an altered risk of new-onset diabetes or impaired fasting glucose in hypertensive patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Registration<\/jats:title>\n                  <jats:p>STEP ClinicalTrials.gov, number: NCT03015311.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwad105","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T10:28:25Z","timestamp":1681122505000},"page":"988-995","source":"Crossref","is-referenced-by-count":6,"title":["Intensive blood pressure lowering and the risk of new-onset diabetes in patients with hypertension: a post-hoc analysis of the STEP randomized trial"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3429-7765","authenticated-orcid":false,"given":"Ruixue","family":"Yang","sequence":"first","affiliation":[{"name":"Hypertension Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences , Beilishi Road 167, Xicheng District, Beijing 100037 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqi","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine , No. 100 Haining Road, Hongkou District, Shanghai 200080 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengdan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of General Practice, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine , No. 100 Haining Road, Hongkou District, Shanghai, 200080 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhua","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Nanchang Sixth Hospital , No. 24 Luojiatang Road, Xihu District, Nanchang, Jiangxi 330003 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Cong","sequence":"additional","affiliation":[{"name":"Hypertension Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences , Beilishi Road 167, Xicheng District, Beijing 100037 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8928-9570","authenticated-orcid":false,"given":"Jun","family":"Cai","sequence":"additional","affiliation":[{"name":"Hypertension Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences , Beilishi Road 167, Xicheng District, Beijing 100037 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,4,10]]},"reference":[{"key":"2023080100353298100_zwad105-B1","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"2023080100353298100_zwad105-B2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S0140-6736(12)60987-8","article-title":"Diabetes and hypertension: the bad companions","volume":"380","author":"Ferrannini","year":"2012","journal-title":"Lancet Lond Engl"},{"key":"2023080100353298100_zwad105-B3","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1093\/eurjpc\/zwac132","article-title":"Lifestyle and metabolic risk factors in patients with early-onset myocardial infarction: a case-control study","volume":"29","author":"Wienbergen","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2023080100353298100_zwad105-B4","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1093\/eurjpc\/zwac205","article-title":"Dose-dependent relationship of blood pressure and glycaemic status with risk of aortic dissection and aneurysm","volume":"29","author":"Suzuki","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"2023080100353298100_zwad105-B5","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/HYPERTENSIONAHA.121.17981","article-title":"Hypertension in diabetes: an update of basic mechanisms and clinical disease","volume":"78","author":"Jia","year":"2021","journal-title":"Hypertens Dallas Tex"},{"key":"2023080100353298100_zwad105-B6","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jacc.2015.07.059","article-title":"Usual blood pressure and risk of new-onset diabetes: evidence from 4.1 million adults and a meta-analysis of prospective studies","volume":"66","author":"Emdin","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2023080100353298100_zwad105-B7","doi-asserted-by":"crossref","first-page":"e003917","DOI":"10.1161\/JAHA.116.003917","article-title":"Different combinations of glucose tolerance and blood pressure Status and incident diabetes, hypertension, and chronic kidney disease","volume":"5","author":"Derakhshan","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"2023080100353298100_zwad105-B8","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2337\/dc08-1881","article-title":"Insufficient control of blood pressure and incident diabetes","volume":"32","author":"Izzo","year":"2009","journal-title":"Diabetes Care"},{"key":"2023080100353298100_zwad105-B9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2337\/db16-0868","article-title":"Systolic blood pressure and risk of type 2 diabetes: a Mendelian randomization study","volume":"66","author":"Aikens","year":"2017","journal-title":"Diabetes"},{"key":"2023080100353298100_zwad105-B10","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1093\/eurheartj\/eht281","article-title":"Hypertensive target organ damage predicts incident diabetes mellitus","volume":"34","author":"Izzo","year":"2013","journal-title":"Eur Heart J"},{"key":"2023080100353298100_zwad105-B11","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1097\/HJH.0b013e328122dd58","article-title":"Diabetes in treated hypertension is common and carries a high cardiovascular risk: results from a 28-year follow-up","volume":"25","author":"Almgren","year":"2007","journal-title":"J Hypertens"},{"key":"2023080100353298100_zwad105-B12","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/eurheartj\/ehv557","article-title":"Contrasting mortality risks among subgroups of treated hypertensive patients developing new-onset diabetes","volume":"37","author":"Lip","year":"2016","journal-title":"Eur Heart J"},{"key":"2023080100353298100_zwad105-B13","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/dom.14295","article-title":"Diabetogenic effects of cardioprotective drugs","volume":"23","author":"Bell","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2023080100353298100_zwad105-B14","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/S0140-6736(21)01920-6","article-title":"Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis","volume":"398","author":"Nazarzadeh","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"2023080100353298100_zwad105-B15","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"The SPRINT Research Group","year":"2015","journal-title":"N Engl J Med"},{"key":"2023080100353298100_zwad105-B16","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","article-title":"Trial of intensive blood-pressure control in older patients with hypertension","volume":"385","author":"Zhang","year":"2021","journal-title":"N Engl J Med"},{"key":"2023080100353298100_zwad105-B17","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","article-title":"ESC\/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension: the task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension","volume":"36","author":"Williams","year":"2018","journal-title":"J Hypertens"},{"key":"2023080100353298100_zwad105-B18","first-page":"e13","article-title":"ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertens Dallas Tex"},{"key":"2023080100353298100_zwad105-B19","doi-asserted-by":"crossref","first-page":"105913","DOI":"10.1016\/j.cct.2019.105913","article-title":"Strategy of blood pressure intervention in the elderly hypertensive patients (STEP): rational, design, and baseline characteristics for the main trial","volume":"89","author":"Zhang","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"2023080100353298100_zwad105-B20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ecl.2013.09.005","article-title":"Type 2 diabetes mellitus and hypertension: an update","volume":"43","author":"Lastra","year":"2014","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2023080100353298100_zwad105-B21","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1751-7176.2011.00439.x","article-title":"Relationships among insulin resistance, type 2 diabetes, essential hypertension, and cardiovascular disease: similarities and differences","volume":"13","author":"Reaven","year":"2011","journal-title":"J Clin Hypertens Greenwich Conn"},{"key":"2023080100353298100_zwad105-B22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1161\/01.HYP.32.2.243","article-title":"Insulin resistance and the effect of insulin on blood pressure in essential hypertension","volume":"32","author":"Heise","year":"1998","journal-title":"Hypertens Dallas Tex"},{"key":"2023080100353298100_zwad105-B23","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s40292-020-00408-8","article-title":"Insulin resistance the hinge between hypertension and type 2 diabetes","volume":"27","author":"Mancusi","year":"2020","journal-title":"High Blood Press Cardiovasc Prev Off J Ital Soc Hypertens"},{"key":"2023080100353298100_zwad105-B24","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/eurheartj\/ehp101","article-title":"Angiotensin II receptor blocker-based vs. Non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the heart institute of Japan candesartan randomized trial for evaluation in coronary artery disease (HIJ-CREATE)","volume":"30","author":"Kasanuki","year":"2009","journal-title":"Eur Heart J"},{"key":"2023080100353298100_zwad105-B25","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.2337\/diacare.28.9.2261","article-title":"The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes","volume":"28","author":"Gillespie","year":"2005","journal-title":"Diabetes Care"},{"key":"2023080100353298100_zwad105-B26","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jacc.2005.05.051","article-title":"Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"46","author":"Abuissa","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2023080100353298100_zwad105-B27","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7326\/0003-4819-139-3-200308050-00006","article-title":"Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial","volume":"139","author":"Devereux","year":"2003","journal-title":"Ann Intern Med"},{"key":"2023080100353298100_zwad105-B28","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet Lond Engl"},{"key":"2023080100353298100_zwad105-B29","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.amjcard.2007.05.057","article-title":"A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus","volume":"100","author":"Bangalore","year":"2007","journal-title":"Am J Cardiol"},{"key":"2023080100353298100_zwad105-B30","doi-asserted-by":"crossref","first-page":"955","DOI":"10.7326\/0003-4819-126-12-199706150-00004","article-title":"Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial","volume":"126","author":"Giugliano","year":"1997","journal-title":"Ann Intern Med"},{"key":"2023080100353298100_zwad105-B31","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1001\/jama.292.18.2227","article-title":"Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial","volume":"292","author":"Bakris","year":"2004","journal-title":"JAMA"},{"key":"2023080100353298100_zwad105-B32","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"key":"2023080100353298100_zwad105-B33","doi-asserted-by":"crossref","first-page":"f6745","DOI":"10.1136\/bmj.f6745","article-title":"Role of diuretics, \u03b2 blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study","volume":"347","author":"Shen","year":"2013","journal-title":"BMJ"},{"key":"2023080100353298100_zwad105-B34","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ahj.2013.12.025","article-title":"Cardiovascular drugs that increase the risk of new-onset diabetes","volume":"167","author":"Ong","year":"2014","journal-title":"Am Heart J"},{"key":"2023080100353298100_zwad105-B35","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","article-title":"Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis","volume":"369","author":"Elliott","year":"2007","journal-title":"Lancet Lond Engl"},{"key":"2023080100353298100_zwad105-B36","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/S0140-6736(21)02340-0","article-title":"Blood pressure lowering in the prevention of type 2 diabetes","volume":"398","author":"Cavender","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"2023080100353298100_zwad105-B37","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.118.12572","article-title":"Blood pressure control and the association with diabetes incidence: results from the SPRINT randomized trial","volume":"75","author":"Roumie","year":"2020","journal-title":"Hypertens Dallas Tex"},{"key":"2023080100353298100_zwad105-B38","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1001\/jama.285.16.2109","article-title":"Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the hoorn study","volume":"285","author":"de Vegt","year":"2001","journal-title":"JAMA"},{"key":"2023080100353298100_zwad105-B39","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2337\/dc06-1392","article-title":"Progression from newly acquired impaired fasting glusose to type 2 diabetes","volume":"30","author":"Nichols","year":"2007","journal-title":"Diabetes Care"},{"key":"2023080100353298100_zwad105-B40","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2337\/dc09-1524","article-title":"Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. Population in 1988\u20132006","volume":"33","author":"Cowie","year":"2010","journal-title":"Diabetes Care"},{"key":"2023080100353298100_zwad105-B41","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.2337\/dc21-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes\u20142021","volume":"44","author":"Association","year":"2021","journal-title":"Diabetes Care"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwad105\/50100770\/zwad105.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/30\/10\/988\/51012287\/zwad105.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/30\/10\/988\/51012287\/zwad105.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:36:24Z","timestamp":1690850184000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/30\/10\/988\/7111613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,10]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,4,10]]},"published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwad105","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,4,10]]}}}